<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-77280</identifier>
<setSpec>1889-7347</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Inflammatory markers in chronic obstructive lung disease</dc:title>
<dc:description xml:lang="en">Introduction: Chronic obstructive lung disease (COPD) provoques extra-thoracic affection, with an important systemic inflammatory process. The objective of this report was to evaluate the protein Creactive (PCR) and the so-called acute phase reactants (APR), less in patients with stable COPD. Methods: Observational, case-control study in which the levels of APR were studied in patients with stable COPD, against healthy smokers. The sample was characterized by testing respiratory function(GOLD), exhaled carbon monoxide, Charlson co-morbidity, degree of dyspnea (MRC), annual number of acute attacks and nutritional evaluation (IMC). Two measurements of APR were carried out during two different visits for each patient, determining PCR, complementary factors, alpha 1-antitrypsin, albumin, prealbumin, haptoglobin, speed of sedimentation and fibrinogen. Results: 69 patients with COPD were included (64 men; 65±8years) and 35 healthy smokers (22 men; 55±0.3 years). PCR, complementary factors 3 and 5, alpha 1-antitrypsin and fibrinogen, were significantly raised in those with COPD (PCR: 5.7±5.9 vs.3±3.09; p = 0.002; C3: 149.57±25.68 vs. 134.04±24.96 p = 0.006;C5: 14.20±5.3 vs. 12.66±5.2; p = 0.01; alpha 1-antitrypsin: 152.51(25.58 vs. 141.22 (25.30; p = 0.02; fibrinogen: 3.8 ± 1.07 vs. 4.2± 1.1; p=0.016). There were no differences between the two determinations for APR. Conclusions: The results of our study reflect that there are diverse APR related to the systemic inflammation in COPD, whose role in the pathogenesis of the extra-thoracic affectation and in the prognosis of the disease must be appropriately studied (AU)</dc:description>
<dc:creator>Rojano, B</dc:creator>
<dc:creator>Delgado, A</dc:creator>
<dc:creator>Calero Acuña, C</dc:creator>
<dc:creator>Cortes, A</dc:creator>
<dc:creator>Márquez Martín, E</dc:creator>
<dc:creator>Cejudo Ramos, P</dc:creator>
<dc:creator>Ortega, F</dc:creator>
<dc:creator>López Campos, JL</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción: la enfermedad pulmonar obstructiva crónica(EPOC) origina una afectación extra torácica con importante participación de un proceso inflamatorio sistémico. El objetivo del presente trabajo fue evaluar la proteína C reactiva (PCR) y los denominados reactantes de fase aguda (RFA) menores en pacientes con EPOC estable. Métodos: estudio observacional de casos-control en el que se estudiaron los niveles de RFA en pacientes con EPOC estable frente a fumadores sanos. La muestra se caracterizó mediante pruebas defunción respiratoria (GOLD), monóxido de carbono exhalado, índice de comorbilidad de Charlson, grado de disnea (MRC),número de agudizaciones anuales y evaluación nutricional (IMC).Se realizaron dos mediciones de RFA en dos visitas diferentes para cada paciente, determinando PCR, factores del complemento,alfa1-antitripsina, albúmina, prealbúmina, haptoglobina, velocidad de sedimentación y fibrinógeno. Resultados: se incluyeron 69 pacientes con EPOC (64 hombres;65±8 años) y 35 fumadores sanos (22 hombres; 55±0,3 años). La PCR, los factores del complemento 3 y 5, la alfa1-antitripsina y el fibrinógeno, estaban significativamente elevados en los EPOC (PCR: 5,7±5,9 vs 3±3,09; p=0,002; C3: 149,57±25,68 vs134,04±24,96 p=0,006; C5: 14,20±5,3 vs 12,66±5,2; p=0,01;alfa1-antitripsina: 152,51±25,58 vs 141,22±25,30; p=0,02; fibrinógeno:3,8±1,07 vs 4,2±1,1; p=0,016). No se encontraron diferencias entre las dos determinaciones de RFA. Conclusiones: los resultados de nuestro estudio reflejan que existen diversos RFA relacionados con la inflamación sistémica en la EPOC, cuyo papel en la patogenia de la afectación extratorácica y en el pronóstico de la enfermedad deben ser adecuadamente estudiados (AU)</dc:description>
<dc:source>Rev. esp. patol. torac;21(2): 76-81, abr.-jun. 2009. tab</dc:source>
<dc:identifier>ibc-77280</dc:identifier>
<dc:title xml:lang="es">Marcadores inflamatorios en la enfermedad pulmonar obstructiva crónica</dc:title>
<dc:subject>^d23568^s22062</dc:subject>
<dc:subject>^d36008^s22062</dc:subject>
<dc:subject>^d22124^s22002</dc:subject>
<dc:subject>^d22307^s22002</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d24551</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:type>article</dc:type>
<dc:date>200906</dc:date>
</metadata>
</record>
</ibecs-document>
